skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The use of anti-tuberculosis therapy for latent TB infection

Review

(2549) Views  (883) Full article downloads

Authors: Justin T Denholm, Emma S McBryde

Published Date July 2010 Volume 2010:3 Pages 63 - 72
DOI: http://dx.doi.org/10.2147/IDR.S8994

Justin T Denholm1,2, Emma S McBryde1,2

1Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia; 2Department of Medicine, (RMH/WH), University of Melbourne, Parkville, Victoria, Australia

Abstract: Tuberculosis infection is of global public health significance, with millions of incident cases each year. Many cases, particularly in low-prevalence settings, result from the reactivation of latent tuberculosis infection (LTBI); potentially acquired years prior to active disease. Up to one-third of the world’s population has been infected with LTBI, and so may be at risk for future active TB disease. A variety of antituberculosis medications and treatment regimens have now been evaluated in the management of LTBI, with the aim of eradicating tuberculosis bacilli and reducing the likelihood of subsequent reactivation disease. This article reviews LTBI therapies and their use in clinical contexts, and considers future directions for individual and population-based strategies in LTBI management.

Keywords: tuberculosis, latent tuberculosis, isoniazid, rifampicin, tuberculin skin test, interferon-gamma release assay







Readers of this article also read:

The determinants of the antibiotic resistance process
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Occult hepatitis B virus infection in Egyptian hemodialysis patients with or without hepatitis C virus infection
Multidrug and extensively drug-resistant tuberculosis from a general practice perspective
Lyme disease: the next decade
Boceprevir in the treatment of chronic hepatitis C virus infection
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings
Treatment of drug-resistant tuberculosis
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
High prevalence of extended-spectrum β-lactamase-producing pathogens: results of a surveillance study in two hospitals in Ujjain, India
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University